



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/100872/2020

European Medicines Agency decision P/0102/2020

of 20 March 2020

on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMA-000145-PIP02-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0102/2020

of 20 March 2020

on the acceptance of a modification of an agreed paediatric investigation plan for denosumab (Prolia, Xgeva), (EMA-000145-PIP02-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0086/2013 issued on 29 April 2013 and the decision P/0058/2016 issued on 18 March 2016,

Having regard to the application submitted by Amgen Europe B.V. on 29 October 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 31 January 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for denosumab (Prolia, Xgeva), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/89/2008 issued on 14 October 2008, including subsequent modifications thereof.

Article 3

This decision is addressed to Amgen Europe B.V., Minervum 7061, 4817-ZK – Breda, The Netherlands.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/601112/2019
Amsterdam, 31 January 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000145-PIP02-12-M02

Scope of the application

Active substance(s):

Denosumab

Invented name:

Prolia

Xgeva

Condition(s):

Treatment of osteoporosis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Amgen Europe B.V.

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Amgen Europe B.V. submitted to the European Medicines Agency on 28 October 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0086/2013 issued on 29 April 2013 and the decision P/0058/2016 issued on 18 March 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 3 December 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of osteoporosis

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of osteoporosis

2.1.1. Indication(s) targeted by the PIP

Treatment of glucocorticoid-induced osteoporosis

Treatment of osteogenesis imperfecta

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable
Non-clinical	0	Not applicable
Clinical	2	Study 1 Open-label single-arm, historically controlled study to evaluate safety, efficacy and pharmacokinetics of denosumab in children from 2 to less than 18 years old with osteogenesis imperfecta. Study 2 Double-blind, placebo-controlled randomised study to evaluate safety and efficacy of denosumab in children from 5 to less than 18 years old with glucocorticoid-induced osteoporosis.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of bone loss associated with sex hormone ablative therapy

Authorised indication(s):

- Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.

2. Prevention of skeletal related events in patients with bone metastases

Authorised indication(s):

- Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.

3. Treatment of giant cell tumour of bone

Authorised indication(s):

- Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

4. Treatment of osteoporosis (*Condition covered by EMEA-000145-PIP02-12 and subsequent modifications thereof*)

Authorised indication(s):

- Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non-vertebral and hip fractures.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use